1023301-84-9

Basic information

• Product Name: tert-Butyl2,7-diazaspiro[3.5]nonane-7-carboxylatehydrochloride
• Synonyms: tert-Butyl2,7-diazaspiro[3.5]nonane-7-carboxylatehydrochloride;2,7-Diazaspiro[3.5]nonane-7-carboxylic acid, 1,1-diMethylethyl ester, (Hydrochloride) (1:1);tert-butyl 2,7-diazaspiro[3.5]nonane-7-carboxylate HCl salt;7-Boc-2,7-diaza-spiro[3.5]nonane hydrochloride
• CAS NO: 1023301-84-9
• Molecular Formula: C₁₂H₂₂N₂O₂*ClH
• Molecular Weight: 261.76828
• Mol File: 1023301-84-9.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 319 ?C
• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: tert-Butyl2,7-diazaspiro[3.5]nonane-7-carboxylatehydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: tert-Butyl2,7-diazaspiro[3.5]nonane-7-carboxylatehydrochloride(1023301-84-9)
• EPA Substance Registry System: tert-Butyl2,7-diazaspiro[3.5]nonane-7-carboxylatehydrochloride(1023301-84-9)

Safety Data

• Hazardous Substances Data: 1023301-84-9(Hazardous Substances Data)

Usage

General Description

Tert-Butyl2,7-diazaspiro[3.5]nonane-7-carboxylate hydrochloride is a chemical compound used in the synthesis of various pharmaceuticals and organic compounds. It is a spiro compound, containing a spirocyclic ring system with a nitrogen atom. The tert-butyl group attached to the nitrogen atom provides stability and protection to the compound. The hydrochloride salt form of the compound makes it more stable and suitable for various chemical reactions. Tert-Butyl2,7-diazaspiro[3.5]nonane-7-carboxylate hydrochloride has potential applications in medicinal chemistry and drug development due to its structural and chemical properties.

InChI:InChI=1/C12H22N2O2.ClH/c1-11(2,3)16-10(15)14-6-4-12(5-7-14)8-13-9-12;/h13H,4-9H2,1-3H3;1H;

Upstream product

• 929302-00-1 tert-butyl 4-cyano-4-({[(4-methylphenyl)sulfonyl]oxy}methyl)piperidine-1-carboxylate 

Downstream Products

• 1334782-54-5 2-(4-methoxyphenyl)-1-{2-[(1R)-5-(pyrimidin-2-yl)-2,3-dihydro-1H-inden-1-yl]-2,7-diazaspiro[3.5]non-7-yl}ethanone 
• 1334785-21-5 5-methyl-2-{2-oxo-2-[2-((R)-5-pyrimidin-2-yl-indan-1-yl)-2,7-diaza-spiro[3.5]non-7-yl]ethyl}benzoic acid 
• 1334783-53-7 5-methyl-2-(2-oxo-2-{2-[(1R)-5-pyrimidin-2-yl-2,3-dihydro-1H-inden-1-yl]-2,7-diazaspiro[3.5]non-7-yl}ethyl)benzamide 
• 1620516-15-5 tert-butyl 2-(5-(2-(benzyloxy)-4-bromo-6-fluorophenyl)-1,3,4-thiadiazol-2-yl)-2,7-diazaspiro[3.5]nonane-7-carboxylate 
• 1227456-92-9 benzyl 2,7-diazaspiro[3.5]nonane-2-carboxylate 
• 1345728-66-6 2-benzyl 7-(tert-butyl) 2,7-diazaspiro[3.5]nonane-2,7-dicarboxylate 

Relevant articles and documents

1-azaspirocycle compound, and preparation method and applications thereof

The invention discloses a 1-azaspirocycle compound, and preparation method and applications thereof, and belongs to the field of pharmaceutical chemistry. The 1-azaspirocycle compound with a structurerepresented by formula I, or a pharmaceutically acceptable salt or a stereisomer or a solvate or a prodrug thereof is capable of realzing combination with Autotaxin, can be taken as an Autotaxin inhibitor, and can be used for prevention and treatment of diseases with Autotaxin expression increasing pathological characteristics such as cancer and fibrosis diseases especially pulmonary fibrosis andhepatic fibrosis, metabolic diseases, myelodysplastic syndrome, cardiovascular diseases, autoimmune diseases, inflammation, neurological diseasses, or pain. Compared with single component inhibitors,the 1-azaspirocycle compound and the derivatives possesses following advantages: blocking and interfacing at the upsteam of a plurality of key signal channels are realized, tumor cell growth and transfer are relieved or dalyed, early caused drug resistance is avoided, and novel means are provided for treatment of tumor cells.